# US 2009/0291950 A1 · Bicyclic heteroaryl inhibitors of pde4

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0291950 A1
- Document ID: US20090291950A1
- Status: Published application
- Kind: A1
- Application number: 12/307,738
- Filed: 2007-07-06
- Published: 2009-11-26
- Earliest claimed: 2006-07-07
- Assignees: Kalypsys, Inc.
- Inventors: Steven P. Govek; Andrew K. Shiau; Stewart A. Noble; David J. Thomas
- Web page: https://patentgrep.com/patent/US20090291950A1

## CPC

- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4704: 2-Quinolinones, e.g. carbostyril
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/14: Decongestants or antiallergics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PD E4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.

## Claims

### Claim 1

A compound of structural Formula II
or a salt, ester, or prodrug thereof, wherein:
X1 is selected from the group consisting of O, N(R14) and (CR15R16);
X2 is selected from the group consisting of (CR18R19), COR18, and null;
X is selected from the group consisting of N(R17) and (CR20R21);
R1 and R2 are independently selected from the group consisting of —(CH2)sG1G2G3, acyl, acylalkyl, carboxyalkyl, cyanoalkyl, alkoxy, alkoxyalkyl, amidoalkyl, amino, alkyl, alkylalkoxy, aminoalkyl, alkenyl, alkynyl, carboxyl, carboxyalkyl, ether, heteroalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aralkyl, aryl, guanidine, heteroaryl, heteroaralkyl, hydrogen and hydroxyalkyl, any of which may be optionally substituted;
s is 1-8;
G1 is selected from the group consisting of alkoxy, amino, amido, carbonyl, hydroxy, ether, an amino acid, and null;
G2 is selected from the group consisting of alkyl, alkoxy, amino, aryl, halo, haloalkyl, heterocycloalkyl, heteroaryl, carboxylalkylamino, guanidine, an amino acid, and null, any of which may be optionally substituted;
G3 is selected from the group consisting of alkyl, alkoxy, amino, hydroxy, ether, carboxyl, hydroxamic acid, an amino acid, phosphonate, phosphoamide, and null, any of which may be optionally substituted;
R3 and R4 are each independently selected from the group consisting of hydrogen, halogen, alkoxy and lower alkyl;
R5 is selected from the group consisting of —(CR8R9)mW(CR10R11)n— and —(CR12R13)p—;
W is selected from the group consisting of O, N(R7), C(O)N(R7), and SOq;
m, n, and q are independently 0, 1 or 2;
p is 1 or 2;
R6 is selected from the group consisting of carboxyl, alkylcarboxy, amido, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl, heteroalkyl, acyl, and hydroxamic acid, any of which may be optionally substituted;
R7, R8, R9, R10, R11, R12, and R13 are independently selected from the group consisting of hydrogen and optionally substituted lower alkyl;
R14 and R17 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, lower alkyl, hydroxyalkyl, haloalkyl, aminoalkyl, and a bond;
R15, R16, R19, R20, and R21 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, haloalkyl, hydroxyalkyl, heterocycloalkylalkyl, alkoxy, haloalkoxy, amino, aminoalkyl, aminoalkoxy and a bond; and
R18 is selected from the group consisting of halogen, lower alkyl, haloalkyl, hydroxyalkyl, heterocycloalkylalkyl, alkoxy, haloalkoxy, amino, aminoalkyl, aminoalkoxy and a bond.

### Claim 2 (depends on 1)

The compound as recited in claim 1, having any one of structural Formulas III, IV, V, or VI
or a salt, ester, or prodrug thereof, wherein:
R1 and R2 are independently selected from the group consisting of —(CH2)sG1G2G3, acyl, acylalkyl, carboxyalkyl, cyanoalkyl, alkoxy, alkoxyalkyl, amidoalkyl, amino, alkyl, alkylalkoxy, aminoalkyl, alkenyl, alkynyl, carboxyl, carboxyalkyl, ether, heteroalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aralkyl, aryl, guanidine, heteroaryl, heteroaralkyl, hydrogen and hydroxyalkyl, any of which may be optionally substituted;
s is 1-8;
G1 is selected from the group consisting of alkoxy, amino, amido, carbonyl, hydroxy, ether, an amino acid, and null;
G2 is selected from the group consisting of alkyl, alkoxy, amino, aryl, halo, haloalkyl, heterocycloalkyl, heteroaryl, carboxylalkylamino, guanidine, an amino acid, and null, any of which may be optionally substituted;
G3 is selected from the group consisting of alkyl, alkoxy, amino, hydroxy, ether, carboxyl, hydroxamic acid, an amino acid, phosphonate, phosphoamide, and null, any of which may be optionally substituted;
R3 and R4 are independently selected from the group consisting of hydrogen, halogen, alkoxy and lower alkyl;
R5 is selected from the group consisting of —(CR8R9)mW(CR10R11)n— and —(CR2R3)p—;
W is selected from the group consisting of O, N(R7), C(O)N(R7), and SOq;
m, n, and q are independently 0, 1 or 2;
p is 1 or 2;
R6 is selected from the group consisting of carboxyl, alkylcarboxy, amido, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl, heteroalkyl, acyl, and hydroxamic acid, any of which may be optionally substituted;
R7, R8, R9, R10, R11, R12, and R13 are independently selected from the group consisting of hydrogen and optionally substituted lower alkyl;
R15 and R20 are each independently selected from the group consisting of hydrogen, halogen, lower alkyl, hydroxyalkyl, heterocycloalkylalkyl, haloalkyl, alkoxy, haloalkoxy, amino, aminoalkyl, and aminoalkoxy; and
R18 is selected from the group consisting of halogen, lower alkyl, hydroxyalkyl, heterocycloalkylalkyl, haloalkyl, alkoxy, haloalkoxy, amino, aminoalkyl, and aminoalkoxy.

### Claim 3 (depends on 2)

The compound as recited in claim 2, wherein R3 and R4 are both hydrogen.

### Claim 4 (depends on 3)

The compound as recited in claim 3, wherein R6 is selected from the group consisting of phenyl, pyridine, pyrimidine, pyridazine, and pyrazine, any of which may be optionally substituted.

### Claim 5 (depends on 4)

The compound as recited in claim 4, wherein:
R5 is —(CR8R9)mW(CR10R11)n—;
m and n are both 0;
W is N(R7); and
R7 is hydrogen.

### Claim 6 (depends on 5)

The compound as recited in claim 5, wherein R2 is lower alkyl.

### Claim 7 (depends on 6)

The compound as recited in claim 6, wherein:
R1 is selected from the group consisting of —(CH2)sG1G2G3, lower alkyl, cycloalkyl, cycloalkylalkyl, and heterocycloalkyl, any of which may be optionally substituted;
s is 1-6;
G1 is selected from the group consisting of amino, amido, and null;
G2 is selected from the group consisting of alkoxy, aryl, halo, heterocycloalkyl, and null, any of which may be optionally substituted; and
G3 is selected from the group consisting of alkyl, carboxyl, and null, any of which may be optionally substituted.

### Claim 8 (depends on 7)

The compound as recited in claim 7, wherein R2 is methyl.

### Claim 9 (depends on 8)

The compound as recited in claim 8, wherein R6 has a formula selected from the group consisting of:
R22, R23, R24, R25 and R26 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, lower alkyl, lower alkoxy, lower haloalkyl, lower haloalkoxy, amino, and carboxyl.

### Claim 10

A compound selected from the group consisting of Examples 1 to 30.

### Claim 11 (depends on 1)

A compound as recited in claim 1 for use as a medicament.

### Claim 12 (depends on 1)

A compound as recited in claim 1 for use in the manufacture of a medicament for the prevention or treatment of a disease or condition ameliorated by the inhibition of PDE4.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising a compound as recited in claim 1 together with a pharmaceutically acceptable carrier.

### Claim 14 (depends on 1)

A method of inhibition of PDE4 comprising contacting PDE4 with a compound as recited in claim 1.

### Claim 15 (depends on 1)

A method of treatment of a PDE4-mediated disease comprising the administration of a therapeutically effective amount of compound as recited in claim 1 to a patient in need thereof.

### Claim 16 (depends on 15)

The method as recited in claim 15 wherein said PDE4-mediated disease is an ophthalmic disease.

### Claim 17 (depends on 16)

The method as recited in claim 16 wherein said ophthalmic disease is selected from the group consisting of dry eye, glaucoma, corneal neovascularization, optic neuritis, Sjogren's syndrome, retinal ganglion degeneration, ocular ischemia, retinitis, retinopathy, uveitis, ocular photophobia, and inflammation and pain associated with acute injury to the eye tissue.

### Claim 18 (depends on 13)

The method as recited in claim 13, wherein said PDE4 is the PDE4B subtype.

### Claim 19 (depends on 1)

A method of treatment of a PDE4-mediated disease comprising the administration of:
a. a therapeutically effective amount of said compound as recited in claim 1; and
b. another therapeutic agent.
